|
|
|
|
|
Aripiprazole
drug data and news
Aripiprazole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Aripiprazole | ||
| Brand Names/Synonyms | Abilify; Abilitat; Aripiprazole; Aripiprazole [Usan]; OPC 31 | ||
| Indication | For the treatment of schizophrenia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. | ||
| Mechanism Of Action | Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5- HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors and moderate affinity for the serotonin reuptake pump. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptor. | ||
| Aripiprazole News (When available) |
Teva Pharma's Generic Equivalent Anticonvulsant Drug Topiramate ... 07 Mar 2006 Teva gets added Topamax tentative FDA OK 07 Mar 2006 Binge eating may be hereditary 07 Mar 2006 Sperling's BestPlaces Uncovers Migraine 'Hot Spots' in the US 07 Mar 2006 Generic Topamax: Available in Canada but not US! Feb 27, 2006 Medical Edge: Many drug options for migraines Feb 11, 2006 Guideline Watch: Practice Guideline for the Treatment of Patients ... Jan 23, 2006 The Diagnosis and Treatment of Substance Abuse/ Dependence and Co ... Jan 23, 2006 Managing migraine with drugs, lifestyle changes Jan 10, 2006 Johnson & Johnson: Fourth Quarter and Year End 2005 Financial ... Jan 24, 2006 Bibliography FOR SLEEP, SEX, AND EATING DISORDERS Jan 23, 2006 Depakote® ER Approved For Acute Manic Or Mixed Episodes ... 12 Dec 2005 How to Break the Chain Dec 10, 2005 Adjunctive Lamotrigine Decreases Primary Generalized Tonic-Clonic ... Dec 9, 2005 Is my high-powered new job making my migraine worse? Dec 8, 2005 Avoiding migraine trigger is just part of solution Dec 4, 2005 59th Annual AES Meeting Dec 2, 2005 Mixing Up Drugs with Similar Names Can Cause Potentially Deadly ... Nov 28, 2005 FDA warns of risk from mixed-up prescriptions Nov 27, 2005 Parents are worried about son's behavior changes Nov 14, 2005 Healthbeat:Epilepsy Drugs for Kids Nov 23, 2005 Secondary Mania in Older Adults Nov 13, 2005 Doctors Alerted to Reported Medication Errors Between TOPAMAX® ... Oct 2, 2005 Cognitive Side Effects of Antiepileptic Drugs in Children Oct 3, 2005 Prevention of migraine episodes, Topamax shows promise - New long ... Sep 27, 2005 NEW LONG-TERM CLINICAL STUDIES AND HEALTH-RELATED QUALITY OF LIFE ... Sep 19, 2005 European survey underscores migraine burden Sep 20, 2005 Books to Bookmark(TM) -Ten New Books Worth a Bookmark for Sept. ... Oct 4, 2005 Cutting into alcoholism Oct 6, 2005 Fewer alcoholics are seeking treatment Sep 18, 2005 FDA warns of risk from mixed-up prescriptions Sep 27, 2005 FDA Warns of Risk From Prescription Mix-Up Sep 27, 2005 Similar names, different drugs Sep 28, 2005 FDA warns of prescription mix-ups Sep 28, 2005 Prescription drug mix-ups prompt FDA admonition Sep 28, 2005 Valley business week in review Oct 3, 2005 Healthcare Professionals Alerted to Reported Medication Errors ... Sep 27, 2005 Letter Warns About Drug Mix-Ups Sep 28, 2005 Hidden Drinkers Come Out of the Closet on Internet's Highest ... Sep 23, 2005 Idiopathic Intracranial Hypertension Presenting With Psychiatric ... Sep 24, 2005 Medication Errors Between TOPAMAX and TOPROL-XL Pose Serious ... Oct 3, 2005 Drug mix-ups lead to health problems Sep 28, 2005 Warning about drug mix-ups Sep 29, 2005 Intravenous Valproate Use in Bipolar II Disorder After Gastric ... Sep 24, 2005 Many meds don't mix with the sun Sep 21, 2005 MEDICINE OVERUSE CAN CAUSE HEADACHE RECURRENCES Sep 12, 2005 The Treatment of Bipolar Disorder – Medications for Mania Sep 13, 2005 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antipsychotics; ATC:N05AX12 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Aripiprazole: Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol. Due to its α1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; weaker inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions). Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY. --> | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one | ||
| Chemical Formula | C23H27Cl2N3O2 | ||
| Molecular Weight | 448.385 g/mol | ||
| Smiles String | C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.537 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 75-146 hours | ||
| Protein Binding [%] | >99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Aripiprazole.html http://www.rxlist.com/cgi/generic/abilify.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00638 | ||
| CAS Registry Number | 129722-12-9 | ||
| KEGG Compound ID | C12564 | ||
| PubChem ID | SID:582954 | ||
| PharmGKB ID | PA10026 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |